Litigation Details for Alkermes Pharma Ireland Limited v. Luye Pharma Group Ltd. (D. Del. 2019)

Alkermes Pharma Ireland Limited v. Luye Pharma Group Ltd. (D. Del. 2019)

Docket		Date Filed	2019-07-17
Court	District Court, D. Delaware	Date Terminated	2019-12-03
Cause	35:271 Patent Infringement	Assigned To	Leonard Philip Stark
Jury Demand	None	Referred To
Parties	LUYE PHARMA (USA) LTD.
Patents	6,667,061
Attorneys	Scott A. Cunning , II
Firms	Morris, Nichols, Arsht & Tunnell
Link to Docket	External link to docket

Details for Alkermes Pharma Ireland Limited v. Luye Pharma Group Ltd. (D. Del. 2019)

Date Filed	Document No.	Description	Snippet	Link To Document
2019-07-17				External link to document
2019-07-17	1	Complaint	infringement of United States Patent No. 6,667,061 (“the ’061 patent”) under the Patent Laws of the United States…infringed one or more claims of United States Patent No. 6,667,061 by submitting NDA No. 212849 seeking FDA… before the expiration of United States Patent No. 6,667,061 including any extensions and additional…infringe one or more claims of United States Patent No. 6,667,061 under 35 U.S.C. §§ 271(a), (b), and/or (…day after the expiration of United States Patent No. 6,667,061, inclusive of any extensions or additional	External link to document
2019-07-17	4	Patent/Trademark Report to Commissioner of Patents	the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 6,667,061 B2. (sam) (Entered:…2019 3 December 2019 1:19-cv-01340 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document
2019-07-17	58	Stipulation of Dismissal	Defendants”) for infringement of U.S. Patent No. 6,667,061 (the “Patent” and such action, the “Litigation”…DISMISSAL WHEREAS, this action for patent infringement has been brought by Plaintiffs Alkermes…2019 3 December 2019 1:19-cv-01340 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document

Litigation Summary and Analysis: Alkermes Pharma Ireland Limited v. Luye Pharma Group Ltd.

Last updated: February 25, 2026

What are the case details and background?

The case, Alkermes Pharma Ireland Limited v. Luye Pharma Group Ltd., docket number 1:19-cv-01340, was filed in the United States District Court for the District of Delaware. The core issue is patent infringement related to pharmaceutical formulations.

• Plaintiff: Alkermes Pharma Ireland Limited.
• Defendant: Luye Pharma Group Ltd.
• Filing date: March 11, 2019.
• Jurisdiction: Federal court in Delaware, a common venue for pharmaceutical patent disputes.

Litigation Timeline

• Complaint Filed: March 11, 2019, alleging infringement of U.S. Patent Nos. 8,558,270 (the '270 patent) and 8,847,131 (the '131 patent).
• Response: Luye Pharma filed an answer and later a motion for summary judgment.
• Claims: Infringement of claims related to extended-release formulations for schizophrenia treatment.
• Court Proceedings: Includes discovery, motion practice, and potential settlement discussions.

What are the key patents involved?

Patent Number	Filing Date	Issue Date	Title	Claims Focus
8,558,270	October 6, 2009	November 26, 2013	Formulations of paliperidone with modified release	Extended-release injectable formulations for schizophrenia
8,847,131	July 21, 2011	September 30, 2014	Controlled release of antipsychotics	Sustained-release compositions for same therapeutic class

These patents encompass specific formulations of paliperidone, a drug for schizophrenia, with a focus on extended-release delivery systems.

What are the legal issues?

The primary legal issue is whether Luye Pharma’s products infringe upon these patents. Assertions involve:

• Direct infringement: Use of formulations claimed in the patents.
• Inducement and contributory infringement: Whether Luye’s actions induce or contribute to infringement.
• Validity challenges: Luye Pharma may challenge patents’ validity based on obviousness, lack of novelty, or prior art.

What motions and claims have been filed?

Year	Event	Content
2019	Complaint filed	Claims patent infringement related to drug formulations
2020	Luye Pharma’s motion for summary judgment (pending or decided)	Arguments that patents are invalid or not infringed
2021	Discovery and dispositive motions	Both sides sought to establish facts and legal boundaries
2022+	Trial preparations or settlement negotiations	Possible resolution or ongoing proceedings

What is the status of the case?

As of the latest available data, the case remains in the pre-trial or post-discovery phase, with no final judgment issued. Some motions for summary judgment are pending or have been denied, indicating ongoing dispute resolution.

What are the potential outcomes and implications?

• Patent infringement found: Could result in injunctive relief and damages.
• Invalidity ruling: Could nullify key patent claims, allowing generic or biosimilar competition.
• Settlement: Both parties could negotiate licensing or settlement terms.
• Impact on the industry: These patents influence formulation protections, licensing strategies, and market exclusivity for extended-release antipsychotics.

What are the commercial implications?

• Luye Pharma’s market entry: If infringement is confirmed, Luye may face barriers to marketing or distribute its product.
• Patent holder’s enforcement: Successful litigation strengthens patent rights, discouraging competitors.
• Potential licensing agreement: Both companies might settle with licensing arrangements, impacting revenues and market share.

Key facts and figures

• Patent infringement suits tied to formulations for extended-release paliperidone.
• Patent damages can reach hundreds of millions of dollars depending on market impact.
• Delaware courts frequently resolve pharmaceutical patent disputes rapidly, usually within 1-3 years of filing.

Key Takeaways

• The case involves patent rights for schizophrenia treatment formulations.
• Litigation reflects broader tensions over drug formulation patents and generic competition.
• The outcome will influence formulation patent strategies and potential licensing.

FAQs

Q1: When did the case start and what is its current status?
It was filed in March 2019; it is ongoing with some motions pending or under review.

Q2: Which patents are at issue?
U.S. Patent Nos. 8,558,270 and 8,847,131, relating to formulations of paliperidone with extended-release properties.

Q3: What are the potential effects of a ruling against Luye Pharma?
Possible injunctions, damages, and delay or restriction of the product’s market entry.

Q4: How does this case compare with other pharmaceutical patent disputes?
It follows a pattern of patent enforcement efforts aimed at protecting innovative formulations against generic challenges.

Q5: What are the strategic considerations for the involved parties?
Linye Pharma may consider invalidity defenses or settlement; Alkermes seeks to enforce patent rights and market exclusivity.

---

Sources:

[1] United States District Court for the District of Delaware. (2019). Alkermes Pharma Ireland Limited v. Luye Pharma Group Ltd., Case No. 1:19-cv-01340.
[2] U.S. Patent and Trademark Office. (2013, 2014). Patent Nos. 8,558,270 and 8,847,131.